NCT01300351 - Comparing the Efficacy and Tolerability of Fulvestrant 500 mg Versus 250 mg in Advanced Breast Cancer Women | Biotech Hunter

Enrollment

249

Participants

Timeline

Start Date

March 31, 2011

Primary Completion Date

March 31, 2014

Study Completion Date

March 31, 2014

Conditions

Breast Cancer

Interventions

DRUG

Fulvestrant

Fulvestrant was supplied as a castor oil based solution in clear neutral glass pre-filled syringes. Each syringe will contain 250 mg of fulvestrant in 5 ml.

DRUG

Placebo

Matching placebo was supplied as a castor oil based solution in clear neutral glass prefilled syringes. Each syringe will contain 5 ml.

Trial Locations (15)

Unknown

Research Site, Beijing

Research Site, Chongqing

Research Site, Dalian

Research Site, Guangzhou

Research Site, Hangzhou

Research Site, Harbin

Research Site, Hefei

Research Site, Jiangsu

Research Site, Kunming

Research Site, Nanning

Research Site, Shandong

Research Site, Shanghai

Research Site, Shijiazhuang

Research Site, Taiyuan

Research Site, Tianjin